Total Responses: 62.
Hours per Response: 1.5.
Total Burden Hours: 93.

3. FAR 52.204–29 for GSA Lease Acquisitions

Respondents: 186.
Responses per Respondent: 1.
Total Responses: 186.
Hours per Response: 2.
Total Burden Hours: 372.

4. FAR 52.204–30 for GSA Lease Acquisitions

Respondents: 124.
Responses per Respondent: 1.
Total Responses: 124.
Hours per Response: 2.
Total Burden Hours: 248.

Note: GSA solicits and awards so few CSO procurements (on average less than 5 per year), the burden is negligible and therefore not included in this estimate. *Obtaining Copies:* Requesters may obtain a copy of the information collection documents from the GSA Regulatory Secretariat Division, by emailing *GSARegSec@gsa.gov.* Please cite ''Information Collection 3090–0322'', in all correspondence.

Richard Speidel,

Deputy Chief Data Officer, General Services Administration.

[FR Doc. 2026–21255 Filed 10–16–26; 8:45 am]

BILLING CODE;P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1784]

Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Scottsdale Research Institute has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 18, 2026. Such persons may also file a written request for a hearing on the application on or before December 18, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on September 8, 2026, Scottsdale Research Institute, 12815 North Cave Creek Road, Phoenix, Arizona 85022, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Ibogaine	7260	I

The company plans to bulk manufacture the listed controlled substance for internal research purposes and to support clinical trials. No other activity for this drug code is authorized for this registration.

Justin Wood,

Deputy Assistant Administrator.

[FR Doc. 2026–21360 Filed 10–16–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1788]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Janssen Pharmaceuticals, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 18, 2026. Such persons may also file a written request for a hearing on the application on or before December 18, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on September 9, 2026, Janssen Pharmaceuticals, Inc., 1440 Olympic Drive, Buildings 1 and 5 and 8 and 20, Athens, Georgia 30601–1645, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methylphenidate	1724	II

The company plans to manufacture the listed controlled substance for the internal use intermediates for sale to its customers. No other activity for this drug code is authorized for this registration.

Justin Wood,

Deputy Assistant Administrator.

[FR Doc. 2026–21369 Filed 10–16–26; 8:45 am]

BILLING CODE 4410–09–P